Use of benzothiopenes to treat and prevent prostate cancer
US7425565B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 23, 2003 |
| Grant date | Sep 16, 2008 |
| Priority date | — |
| Expiry date | Jun 15, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a method for treating and preventing prostate cancer, and particularly androgen-independent prostate cancer, the method including administering to a mammal a benzothiopene having the formulaor pharmaceutically acceptable salts or prodrugs thereof, wherein R and R1 are each independently selected from the group consisting of hydrogen, —COR2, —COR3, and R4; R2 is selected from the group consisting of hydrogen, C1-C14 alkyl, C1-C3 chloroalkyl, C1-C3 fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, and phenyl; R3 is phenyl with at least one substitution selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro, trichloromethyl, and trifluoromethyl; R4 is selected from the group consisting of C1-C4 alkyl, C5-C7 cycloalkyl, and benzyl; and R5 is selected from the group consisting of oxygen and —C═O. The method may further include the administration of an estrogen lowering drug to enhance efficacy of the compound of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.